# UNAIR Inactivated COVID-19 Vaccine Phase III (Immunobridging Study)

> **NCT05508477** · PHASE3 · UNKNOWN · sponsor: **Dr. Soetomo General Hospital** · enrollment: 4005 (estimated)

## Conditions studied

- COVID-19 Pandemic
- COVID-19 Vaccines

## Interventions

- **BIOLOGICAL:** Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg
- **BIOLOGICAL:** CoronaVac Biofarma COVID-19 Vaccine

## Key facts

- **NCT ID:** NCT05508477
- **Lead sponsor:** Dr. Soetomo General Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-28
- **Primary completion:** 2023-03-28
- **Final completion:** 2023-05-28
- **Target enrollment:** 4005 (ESTIMATED)
- **Last updated:** 2022-08-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05508477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05508477, "UNAIR Inactivated COVID-19 Vaccine Phase III (Immunobridging Study)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05508477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*